UAMS' InterveXion Gets Another $13.8M for Drug Therapy Trials
The federal grant money will fund a mid-stage clinical trial of a drug that could help meth users break their addiction. read more >
The federal grant money will fund a mid-stage clinical trial of a drug that could help meth users break their addiction. read more >
InterveXion Therapeutics of Little Rock, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, announced Monday the appointment of Keith Ward, Ph.D., to president and CEO. read more >
InterveXion Therapeutics LLC, a University of Arkansas for Medical Sciences BioVentures startup company, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction. read more >
